Literature DB >> 10823799

CD4+ and CD8+ T cells mediate adoptive immunity to aerosol infection of Mycobacterium bovis bacillus Calmette-Guérin.

C G Feng1, W J Britton.   

Abstract

An adoptive-transfer model using recombinase activation gene-deficient (RAG-1-/-) mice was developed to evaluate CD4+ and CD8+ T cell responses to infection with Mycobacterium bovis bacillus Calmette-Guérin (BCG). After receiving immune, unfractionated T cells or T cell subsets isolated by fluorescence-activated cell sorter, the RAG-1-/- mice were exposed to aerosol BCG, and the bacteria load in the infected organs was examined 4 weeks later. Adoptive immunity was expressed more effectively in the spleens than in the lungs. Although CD4+ or unfractionated T cells protected both lungs and spleens, CD8+ T cells conferred significant protection only in the spleens and not in the lungs. The results confirm that in addition to CD4+, CD8+ T cells also play a role in the prevention of bacterial dissemination. This transfer model may be useful for dissecting T cell responses to mycobacterial infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823799     DOI: 10.1086/315466

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis.

Authors:  C G Feng; U Palendira; C Demangel; J M Spratt; A S Malin; W J Britton
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

2.  A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.

Authors:  Daniel F Hoft; Azra Blazevic; Getahun Abate; Willem A Hanekom; Gilla Kaplan; Jorge H Soler; Frank Weichold; Larry Geiter; Jerald C Sadoff; Marcus A Horwitz
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

Review 3.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

4.  BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults.

Authors:  Srabanti Rakshit; Asma Ahmed; Vasista Adiga; Bharath K Sundararaj; Pravat Nalini Sahoo; John Kenneth; George D'Souza; Wesley Bonam; Christina Johnson; Kees Lmc Franken; Tom Hm Ottenhoff; Greg Finak; Raphael Gottardo; Kenneth D Stuart; Stephen C De Rosa; M Juliana McElrath; Annapurna Vyakarnam
Journal:  JCI Insight       Date:  2019-12-19

5.  Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease.

Authors:  D S S Rodrigues; E A S Medeiros; L Y Weckx; W Bonnez; R Salomão; E G Kallas
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

6.  High-frequency vaccine-induced CD8⁺ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection.

Authors:  Thomas Lindenstrøm; Claus Aagaard; Dennis Christensen; Else M Agger; Peter Andersen
Journal:  Eur J Immunol       Date:  2014-03-27       Impact factor: 5.532

7.  Gamma interferon responses of CD4 and CD8 T-cell subsets are quantitatively different and independent of each other during pulmonary Mycobacterium bovis BCG infection.

Authors:  Patricia Ngai; Sarah McCormick; Cherrie Small; Xizhong Zhang; Anna Zganiacz; Naoko Aoki; Zhou Xing
Journal:  Infect Immun       Date:  2007-02-16       Impact factor: 3.441

Review 8.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

Authors:  Joshua S M Woodworth; Samuel M Behar
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

9.  Suboptimal Antigen Presentation Contributes to Virulence of Mycobacterium tuberculosis In Vivo.

Authors:  Patricia S Grace; Joel D Ernst
Journal:  J Immunol       Date:  2015-11-16       Impact factor: 5.422

Review 10.  Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Authors:  Else Marie Agger
Journal:  Adv Drug Deliv Rev       Date:  2015-11-17       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.